Aflibercept (Afiveg) vs Brolucizumab-Dbll

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Aflibercept (Afiveg)

Marketed by STADA Arzneimittel and partners

fusion protein
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Aflibercept (Afiveg): no structured comparison results are available for Age-Related Macular Degeneration.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aflibercept (Afiveg)'s landscape · Brolucizumab-Dbll's landscape